Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 7(1): e29596, 2012.
Article in English | MEDLINE | ID: mdl-22247781

ABSTRACT

Trypanosoma cruzi is an organism highly resistant to ionizing radiation. Following a dose of 500 Gy of gamma radiation, the fragmented genomic DNA is gradually reconstructed and the pattern of chromosomal bands is restored in less than 48 hours. Cell growth arrests after irradiation but, while DNA is completely fragmented, RNA maintains its integrity. In this work we compared the transcriptional profiles of irradiated and non-irradiated epimastigotes at different time points after irradiation using microarray. In total, 273 genes were differentially expressed; from these, 160 were up-regulated and 113 down-regulated. We found that genes with predicted functions are the most prevalent in the down-regulated gene category. Translation and protein metabolic processes, as well as generation of precursor of metabolites and energy pathways were affected. In contrast, the up-regulated category was mainly composed of obsolete sequences (which included some genes of the kinetoplast DNA), genes coding for hypothetical proteins, and Retrotransposon Hot Spot genes. Finally, the tyrosyl-DNA phosphodiesterase 1, a gene involved in double-strand DNA break repair process, was up-regulated. Our study demonstrated the peculiar response to ionizing radiation, raising questions about how this organism changes its gene expression to manage such a harmful stress.


Subject(s)
Biomarkers/metabolism , DNA, Kinetoplast/radiation effects , Gamma Rays , Gene Expression/radiation effects , Genes, Protozoan/genetics , Trypanosoma cruzi/genetics , Dose-Response Relationship, Radiation , Gene Expression Profiling , Oligonucleotide Array Sequence Analysis , RNA, Messenger/genetics , Real-Time Polymerase Chain Reaction , Trypanosoma cruzi/growth & development
2.
Mutat Res ; 599(1-2): 105-15, 2006 Jul 25.
Article in English | MEDLINE | ID: mdl-16574164

ABSTRACT

Due to the essential role played by DNA topoisomerases (topos) in cell survival, the use of topoisomerase inhibitors as chemotherapeutic drugs in combination with radiation has become a common strategy for the treatment of cancer. Catalytic inhibitors of these enzymes would be promising to improve the effectiveness of radiation and therefore, it appears reasonable to incorporate them in combined modality trials. In this work, we have investigated the capacity of both ICRF-193 and Aclarubicin (ACLA), two catalytic inhibitors of topoisomerase II (Topo II), to modulate radiation response in Chinese hamster V79 cell line and its radiosensitive mutant irs2. We also have explored potential mechanisms underlying these interactions. Experiments were performed in the presence and absence of either ICRF-193 or ACLA, and topo II activity was measured using an assay based upon decatenation of kinetoplast DNA (kDNA). For the combined experiments cells were incubated for 3 h in the presence of various inhibitor concentrations and irradiated 30 min prior to the end of treatments and cell survival was determined by clonogenic assay. DNA-damaging activity was measured by single-cell gel electrophoresis. Our results demonstrate that combinations of catalytic inhibitors of topo II and radiation produce an increase in cell killing induced by ionising radiation. The mechanism of radiation enhancement may involve a direct or indirect participation of topo II in the repair of radiation-induced DNA damage.


Subject(s)
Radiation Tolerance/physiology , Topoisomerase II Inhibitors , Aclarubicin/pharmacology , Animals , Cell Line , Cell Survival/drug effects , Cell Survival/genetics , Cell Survival/radiation effects , Cricetinae , DNA Damage , DNA, Kinetoplast/drug effects , DNA, Kinetoplast/genetics , DNA, Kinetoplast/radiation effects , Diketopiperazines , Enzyme Inhibitors/pharmacology , Humans , Insulin Receptor Substrate Proteins , Intracellular Signaling Peptides and Proteins , Mutation , Neoplasms/therapy , Phosphoproteins/genetics , Piperazines/pharmacology , Radiation Tolerance/drug effects , Radiation Tolerance/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...